Erschienen in:
31.07.2021 | Original Article
Metabolic syndrome and the risk of colorectal cancer: a systematic review and meta-analysis
verfasst von:
Xiaoding Shen, Yong Wang, Rui Zhao, Qianyi Wan, Yutao Wu, Lihao Zhao, Xiaoting Wu
Erschienen in:
International Journal of Colorectal Disease
|
Ausgabe 10/2021
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Observational studies have reported an association between metabolic syndrome (MetS) and colorectal cancer risk with inconsistent risk estimates. We conducted this meta-analysis to evaluate the risk of colorectal cancer in individuals with MetS.
Methods
PubMed, Embase, and Web of Science were searched for related studies from database inception to 21 January 2021. Risk estimates for colorectal cancer were extracted from individual articles and pooled using a fixed-effect or random-effect model according to the heterogeneity.
Results
MetS was significantly associated with a higher risk of colorectal cancer in both sexes (relative risk [RR] 1.36, 95% confidence interval [CI] 1.26–1.47, P < 0.001), men (RR 1.33, 95% CI 1.21–1.47, P < 0.001), and women (RR 1.34, 95% CI 1.19–1.52, P < 0.001). The risk of colorectal cancer seemed to increase as the number of MetS components rose. Moreover, the high body mass index (BMI)/waist circumference (WC) and hyperglycemia were all significantly associated with a higher risk of colorectal cancer (RR 1.28 [1.20–1.37] and 1.31 [1.14–1.50] in both sexes, RR 1.31 [1.19–1.45] and 1.23 [1.03–1.46] in men, and RR 1.22 [1.02–1.46] and 1.63 [1.16–2.28] in women, respectively).
Conclusions
MetS was significantly associated with a higher risk of colorectal cancer. The high BMI/WC or hyperglycemia might largely account for this association. Further analysis suggested that, as the number of MetS components increased, the risk of colorectal cancer rose.